Rich Vaillant

Richard Vaillant has over 30 years of experience in the pharmaceutical and medical device sectors in the life sciences industry.

Prior to joining Bionova Scientific as Chief Financial Officer, Rich served as Director of Portfolio Company Financial Operations of Great Point Partners. Prior to Joining Great Point Partners, he served as Chief Financial Officer of Vitalink Research, a Clinical Trial Services site management organization a former GPP II portfolio company.

Prior to Vitalink Research, Mr. Vaillant served as the Chief Financial Officer of Cytovance Biologics (CDMO), a former GPP I portfolio company (7.4x return on invested capital). During his tenure at Cytovance (2011 -2016), revenues grew at a 45% CAGR. In prior roles, Rich served as Chief Financial Officer of Histogenics Corporation a tissue regeneration company, and as Corporate Operations Controller of American Cystoscope Makers, Inc., a Urology, Endoscopy, and Gynecology medical device manufacturing company. Previously, he spent over a decade at Boston Scientific Corporation, a multi-billion-dollar medical device manufacturer as Division Controller for two divisions (Meditech and Meadox).

Rich earned a B.S. in Accounting from Merrimack College and an M.S. in Accounting from Suffolk University.